Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naive type 2 diabetes: Design and population

被引:11
|
作者
Bonadonna, R. C. [1 ]
Giaccari, A. [2 ,3 ]
Buzzetti, R. [4 ]
Aimaretti, G. [5 ]
Cucinotta, D. [6 ]
Avogaro, A. [7 ]
Perseghin, G. [8 ]
Larosa, M. [9 ]
Bolli, G. B. [10 ]
Fanelli, C. G. [10 ]
机构
[1] Univ Parma, Div Endocrinol & Metab Dis, Dept Med & Surg, AOU Parma, Via Gramsci 14, I-43126 Parma, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Rome, Italy
[4] Sapienza Univ Rome, Rome, RM, Italy
[5] Univ Eastern Piedmt, Vercelli, VC, Italy
[6] Univ Messina, Messina, Italy
[7] Univ Padua, Padua, Italy
[8] Univ Milano Bicocca, Milan, MI, Italy
[9] Sanofi, Milan, Italy
[10] Perugia Univ, Sect Endocrinol & Metab, Dept Med, Med Sch, Perugia, Italy
关键词
Type; 2; diabetes; Insulin glargine 300 U/mL; Patient empowerment; Insulin titration; GLYCEMIC CONTROL; CLINICAL INERTIA; PEOPLE; INTENSIFICATION; HYPOGLYCEMIA; INITIATION; BARRIERS;
D O I
10.1016/j.numecd.2019.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: Fostering patient's self-managing of basal insulin therapy could improve glucose control, by removing patient's and physician's barriers to basal insulin initiation, titration and glucose monitoring. The Italian Titration Approaches Study (ITAS) aims at demonstrating non-inferiority (<0.3% margin) in efficacy of glucose control (change in glycated hemoglobin [HbA1c] after 24 weeks) by the same titration algorithm of insulin glargine 300 U/mL (Gla-300), managed by the (nurse assisted) patient versus the physician, in insulin naive patients with Type 2 Diabetes Mellitus (T2DM), uncontrolled with previous treatments. Methods and results: ITAS is a phase IV, 24-week, national, multicenter, open label, randomized (1:1) parallel group study. 458 patients were enrolled, 359 randomized, and 339 completed the study, in 46 Italian centers. Baseline characteristics and previous medications of the ITT population (N = 355) are reported. Mean +/- SD age, T2DM duration, HbA1c, FPG and BMI were 64.0 +/- 9.8 years, 11.6 +/- 7.6 years, 8.79 +/- 0.65%, 170.9 +/- 42.3 mg/dL, and 30.3 +/- 5.6 kg/m(2) , respectively. Vascular and metabolic disorders were most frequent (73.8% and 58.3%, respectively). More than 90% of patients were on metformin. Conclusion: ITAS is the first study to compare two different managers (nurse-assisted patient vs physician) of the same titration algorithm of Gla-300 in insulin naive patients with T2DM in unsatisfactory glucose control. This study might provide novel evidence on the efficacy/ Acronyms: effectiveness of patient-managed titration algorithm of Gla-300 in a pragmatic setting and may reduce barriers to basal insulin initiation and its titration. (C) 2019 Published by Elsevier B.V. on behalf of The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University.
引用
收藏
页码:496 / 503
页数:8
相关论文
共 50 条
  • [41] Similar glycaemic control and less or comparable hypoglycaemia with insulin glargine 300 U/ml vs degludec 100 U/ml in insulin naive type 2 diabetes: the BRIGHT randomised study
    Cheng, A.
    Rosenstock, J.
    Ritzel, R.
    Bosnyak, Z.
    Devisme, C.
    Stella, P.
    Cali, A. M. G.
    Wang, X.
    Frias, J.
    Roussel, R.
    Bolli, G. B.
    DIABETOLOGIA, 2018, 61 : S42 - S42
  • [42] Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus
    Blair, Hannah A.
    Keating, Gillian M.
    DRUGS, 2016, 76 (03) : 363 - 374
  • [43] Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus
    Hannah A. Blair
    Gillian M. Keating
    Drugs, 2016, 76 : 363 - 374
  • [44] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA
    Bogdanovic, M.
    Fournier, M.
    Vitezic, D.
    VALUE IN HEALTH, 2018, 21 : S131 - S132
  • [45] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SLOVENIA
    Bogdanovic, M.
    Krnel, Rados S.
    Foumier, M.
    VALUE IN HEALTH, 2017, 20 (09) : A481 - A481
  • [46] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA
    Bogdanovic, M.
    Mihajlovic, J.
    Fournier, M.
    VALUE IN HEALTH, 2018, 21 : S133 - S133
  • [47] Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naive people with type 2 diabetes initiating basal insulin glargine 100 U/mL
    Landgraf, Wolfgang
    Owens, David R.
    Frier, Brian M.
    Zhang, Mei
    Bolli, Geremia B.
    DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 315 - 323
  • [48] Basal insulin peglispro versus insulin glargine in insulin-naive type 2 diabetes: IMAGINE 2 randomized trial
    Davies, M. J.
    Russell-Jones, D.
    Selam, J. -L.
    Bailey, T. S.
    Kerenyi, Z.
    Luo, J.
    Bue-Valleskey, J.
    Ivanyi, T.
    Hartman, M. L.
    Jacobson, J. G.
    Jacober, S. J.
    DIABETES OBESITY & METABOLISM, 2016, 18 (11): : 1055 - 1064
  • [49] Clinical Outcome Assessment of the Effectiveness of Insulin Degludec (Degludec) in Real-life Medical Practice (CONFIRM)-A Comparative Effectiveness Study of Degludec and Insulin Glargine 300U/mL (Glargine U300) in Insulin-Naive Patients with Type 2 Diabetes (T2D)
    Tibaldi, Joseph
    Haldrup, Steffen
    Sandberg, Viktor
    Wolden, Michael L.
    Rodbard, Helena W.
    DIABETES, 2018, 67
  • [50] New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
    Goldman, Jennifer
    White, John R., Jr.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (10) : 1153 - 1161